Aug 02, 2024
With the growing global health concern regarding obesity, Novo’s WEGOVY (semaglutide) has emerged as a leading solution in the weight loss treatment market. WEGOVY is a GLP-1 receptor agonist used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a weekly subcu...
Read More...
Nov 10, 2021
Obesity is one of the significant global health challenges, having a severe socio-economic impact. It is basically an imbalance in calories consumed versus calories expended. Over the past two to three decades, it has grown to be a global epidemic and impacting people across age and geographic regions, which ...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper